Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1996-9-26
|
pubmed:abstractText |
The purpose of this study was to use a replicate designed trial to assess the overall, intra- and inter-subject variabilities in pharmacokinetic parameters of CGP 33101 after oral administration of tablets relative to that of powder suspended in water, and to determine the relative proportion of the intra-subject variance to the overall variability.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0724-8741
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1878-82
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8786960-Administration, Oral,
pubmed-meshheading:8786960-Adult,
pubmed-meshheading:8786960-Analysis of Variance,
pubmed-meshheading:8786960-Anticonvulsants,
pubmed-meshheading:8786960-Chromatography, High Pressure Liquid,
pubmed-meshheading:8786960-Humans,
pubmed-meshheading:8786960-Male,
pubmed-meshheading:8786960-Middle Aged,
pubmed-meshheading:8786960-Time Factors,
pubmed-meshheading:8786960-Triazoles
|
pubmed:year |
1995
|
pubmed:articleTitle |
Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension.
|
pubmed:affiliation |
Bioanalytics and Pharmacokinetics, Ciba Pharmaceuticals Division, Summit, New Jersey 10502, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|